Oxidative imbalance and lipid peroxidation in Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 446-451

  Praticò, Domenico ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Isoprostanes; Lipid peroxidation; Oxidative stress

Indexed keywords

ISOPROSTANE; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALZHEIMER DISEASE; DRUG ACCUMULATION; EXTRACELLULAR MATRIX; GENETIC RISK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; LIPID PEROXIDATION; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; TISSUE INJURY;

EID: 0036660465     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10097     Document Type: Review

References (47)

1. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. 2001. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease. Arch Neurol 58:373-379.
2. Arai H, Clark CM, Ewbank DC, Takase S, Higuchi S, Miura M, Seki H, Higuchi M, Matsui T, Lee VMY, Trojanowsld JQ, Sasaki H. 1998. Cerebrospinal fluid tau as a potential diagnostic marker in Alzheimer's disease. Neurobiol Aging 19:125-126.
3. Balazs L, Leon M. 1994. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19:1131-1137.
4. Bird BP, Silas S, Hung O, Hadley M, Draper HH. 1983. Determination of malonaldehyde in biological material by high-pressure liquid chromatography. Anal Biochem 128:240-244.
5. Bourdel-Marchyasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reigner B, Emeriau JP, Rainfray M. 2001. Antioxidant defenses and oxidative markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30:235-241.
6. Calingasan NY, Uchida K, Gibson GE. 1999. Protein-bound aerolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72:751-756.
7. Clark CM. 2000. Clinical manifestations and diagnostic evaluation of patients with Alzheimer's disease. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill. p 95-114.
8. Coyle JT, Oster-Granite ML, Gearhart JD. 1986. The neurobiologic consequences of Down syndrome. Brain Res Bull 16:773-787.
9. Draper HH, Hadley M. 1990. Malondialdehyde determination as index of lipid peroxidation. Meth Enzymol 186:421-431.
10. Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Rad Biol Med 11:81-128.
11. Frankel EN. 1991. Recent advances in lipid oxidation. J Sci Food Agric 54:495-511.
12. Flicker C, Ferris SH, Reisberg B. 1991. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41:1006-1009.
13. Floyd RA. 1999. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236-245.
14. Gutteridge JMC. 1986. Aspects to consider when detecting and measuring lipid peroxidation. Free Rad Res Commun 1:173-184.
15. Halliwell B, Chirico S. 1993. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 57:715S-725S.
16. Halliwell B, Gutteridge JMC. 1999. Free radicals in biology and medicine, 3rd ed. Oxford: Oxford University Press.
17. Hazen SL, Hsu FF, d'Avignon, Heinecke JW. 1998. Human neutrophils employ myloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry 37:6864-6873.
18. Janero DR. 1990. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and pereoxidative tissue injury. Free Bad Biol Med 9:515-540.
19. Jeandel C, Nicolas NIB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. 1989. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35:275-282.
20. Khachaturian ZS. 1985. Diagnosis of Alzheimer's disease. Arch Neurol 42:1097-1105.
21. α-VI, in human urine. J Biol Chem 273:29295-29301.
22. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. 1995. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594-1601.
23. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. 1997. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18:457-461.
24. Lovell MA, Xie C, Markesbery WR. 2001. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-194.
25. Markesbery WR, Lovell MA. 1998. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36.
26. 2-like compounds are produced in xivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87:9383-9387.
27. 2-isoprostanes) are formed in situ in phospholipids. Proc Natl Acad Sci USA 89:10721-10725.
28. Petersen RC. 1995. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist 1:326-344.
29. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147:1-10.
30. Praticò D. 2002. Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 63:563-567.
31. Praticò D, Delanty N. 2000. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109:577-585.
32. Praticò D, Trojanowski JQ. 2000. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol Aging 21:441-445.
33. 2α. J Biol Chem 270:9800-9808.
34. 2α-I: a novel index of lipid peroxidation in humans. Proc Natl Acad Sci USA 95:3449-3454.
35. 2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation in vivo. FASEB J 12:177-178.
36. 2α-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809-812.
37. 2α-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 48:795-798.
38. 2-isoprostanes in biology and medicine. Trend Endocr Metabol 12:243-247.
39. Praticò D, Clark CM, Liun F, Rokach J, Lee V MY, Trojanowsld JQ. 2002. Increase of oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch Neurol 59:972-976.
40. Roberts LJ, Morrow JD. 1997. The generation and actions of isoprostanes. Biochim Biophys Acta 1345:121-135.
41. Selley ML. 1997. Determination of the lipid peroxidation product (E)-4-hydroxy-2-nonenal in clinical samples by gas chromatography-negative-ion chemical ionisation mass spectrometry of the O-pentafluorobenzyloxime. J Chromatogr B Biomed Sci Appl 691:263-268.
42. Subbarao KV, Richardson JS, Ang LC. 1990. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55:342-345.
43. Thorpe SR, Baynes JW. 1996. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9:69-77.
44. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. 2001. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54:565-568,
45. 2α excretion in man. J Pharmacol Exp Ther 275:94-100.
46. Yeo H, Helbock HJ, Chyu DW, Ames BN. 1994. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 220:391-396.
47. Zabar Y, Kawas CH. 2000. Epidemiology and clinical genetics of Alzheimer's disease. In: Clark GM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, p 79-94.